$SCL

Stepan Company Q2 2026 Earnings Call Summary

Strategic Performance Drivers Adjusted EBITDA growth of 45% was driven by a combination of 6% organic volume growth, disciplined pricing execution, and ramping productivity gains. Surfactant performance benefited from broad-based demand across all end markets, specifically led by industrial cleaning, laundry, and oil field sectors. Margin recovery was achieved through the rigorous application of contractual pass-through mechanisms and pricing actions to offset fluctuating raw material costs.

Original reporting
Published Jul 31, 2026, 10:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 11:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stepan Company Q2 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$SCLNeutralMed
01

Why it matters

Management attributes strong adjusted EBITDA growth to organic volume, pricing, and productivity, but flags 2H 2026 EBITDA headwinds from normalization of customer pre-buying, plus maintenance turnaround costs. It also discloses sizable restructuring charges and a 2026 savings program aimed at deleveraging and positive free cash flow.

02

Market read

The call provides quantified forward-looking cost savings, restructuring charges, and 2H EBITDA headwinds that can drive near-term revisions to 2026 earnings estimates and valuation.

03

What to watch

The article notes mixed raw-material moves (coconut oil down, other oil-related inputs up) and pass-through effectiveness; traders may need to model net pricing versus cost volatility rather than rely on headline margin recovery.

Relevance 7/10Novelty 6/10Timing: ahead of 2H 2026 earnings modeling and positioning after the Q2 call

Background

This is a Q2 2026 earnings call summary for Stepan, focusing on adjusted EBITDA drivers, segment performance, and 2026 restructuring and savings initiatives.

Company-level read

Ticker impact

$SCLNeutralMedium confidence
Context

Stepan guided on 2026 pre-tax savings ($60M+), restructuring charges ($75M-$80M), and a $5M-$10M EBITDA headwind from normalized customer pre-buying.

Expected impact

Moderate near-term downside risk to 2H 2026 EBITDA expectations, partially offset by the disclosed 2026 savings run-rate.

Evidence & confidence

The article provides specific 2026 savings targets, quantified 2H EBITDA headwind, and restructuring/turnaround costs, which can directly reset forward earnings and margin models.

Market effects

Highlights how surfactant and polymers demand can be distorted by geopolitical inventory pre-buying, affecting sector-wide forecasting assumptions.

North American production utilization and site optimization may influence regional supply tightness and pricing dynamics.

Geopolitical uncertainty (Iran conflict) is cited as a driver of customer inventory behavior, relevant to global demand visibility for specialty chemicals.

Counterpoint

The disclosed $60M+ 2026 pre-tax savings and productivity gains could outweigh the stated 2H EBITDA headwind if normalization is less severe than management’s range implies.

Key entities

  • Stepan Company

    Discussed Q2 performance drivers, 2026 savings targets, 2H EBITDA headwinds, maintenance costs, and restructuring charges.

  • Project Catalyst

    Cost-savings initiative targeting over $60M in pre-tax savings for 2026 and a $22M per-quarter run rate by year-end.

  • Fieldsboro, Millsdale, Stalybridge

    Sites referenced in restructuring and closure/decommissioning charges.

Related articles

$SCLMedAI 8/10

Stepan Reports Second Quarter 2026 Results

Stepan (NYSE: SCL) reported Q2 2026 net income of $22.9M, up 102% year over year, and adjusted net income of $27.1M, up 126%. Adjusted EBITDA rose 45% to $74.4M. Net sales increased 15% to $684.1M, with organic volume up 6%. Free cash flow was -$15.0M due to working capital. The company plans to cut about 100 salaried roles under Project Catalyst and expects full-year restructuring charges of $75.0M-$80.0M.

$SCLMed

STEPAN CO (SCL): Results of Operations and Financial Condition

STEPAN CO (SCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d139905dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Stepan Reports Second Quarter 2026 Results Northbrook, Illinois, July 29, 2026 — Stepan Company (NYSE: SCL) today reported: Second Quarter 2026 Highlights • Reported net income was $22.9 million, up 102% versus the prior ye

$RYMMedAI 8/10

Daily NZX update, Wednesday, June 3, 2026

NZX50 was down 0.3% at 3:00pm, though up 0.4% over five sessions and 6.5% over 12 months. Gentrack Group led gainers (+4%), while Vista Group fell the most (-3%). Ebos (-3%) and A2 Milk (-1%) also declined. Ryman Healthcare is considering new six-year secured bonds; Scales Corp declared a 12.5c FY2025 final dividend; Pacific Edge raised NZ$36.1m at NZ$0.17/share.

$SCLHighAI 9/10

Daily NZX update, Wednesday, May 27, 2026

The NZX50 rose 0.7% to extend gains to 3.1% over five days and 3.1% for the month (still down 2.0% over six months; up 4.6% YoY). Kathmandu Holdings jumped 14% and KMD reported Q3 FY26 sales +5.2% YoY and gross margin 58.2% (+258 bps). Vista Group gained 4% on a new five-year Cinemex deal; PaySauce revenue rose 3% to $9.2m.

$DLXMed

Deluxe Q2 Earnings Call Highlights

Deluxe (NYSE:DLX) reported Q2 segment results, led by Data Solutions revenue up 21.4% to $82.3M and adjusted EBITDA of $18.1M. Merchant Services revenue rose 6.1% to $107.6M. Print revenue fell 4.3% to $235.9M. Deluxe closed its Celero acquisition on July 31 and raised 2026 guidance: revenue $2.095B-$2.12B, adj. EBITDA $455M-$475M, adj. EPS $3.60-$4.00, and FCF about $200M.

$NEOGMedAI 8/10

Neogen (NEOG) Q4 2026 Earnings Call Transcript

Neogen (NEOG) reported fiscal Q4 2026 revenue of $225.3 million, up 4.3% in core growth, led by Food Safety. Adjusted gross margin rose to 49.7% and adjusted EBITDA grew 12% to $45.4 million. FY2027 guidance: revenue $880-$885 million and adjusted EBITDA $180-$182 million. The company plans a 50% R&D increase and a $140 million genomics divestiture for debt reduction.